Designing Longevity
Skip to main content

Compare Brain Health Options

The right starting point depends on what has changed. Use the focus and memory guide for cognitive symptoms, the caregiver guide if you are concerned about someone else, or the headache guide for recurring attacks. The comparison shows where evidence comes from and which uses the studied products actually address.

Sources reviewed November 13, 2026 · How we work

Focused comparisons

What would you like help with?

Products and peptide evidence

Investigational use for cognition

Intranasal regular human insulin in a clinical trial

A phase 2/3 trial used Humulin R U-100 with a study nasal device in adults with a memory-related form of mild cognitive impairment or Alzheimer’s disease dementia. The main analysis found no cognitive or day-to-day functional benefit after 12 months. This was a research use of insulin.

Investigational use for Alzheimer’s disease

Oral semaglutide studied in early Alzheimer’s disease

Two phase 3 trials studied oral semaglutide up to 14 mg in adults with early symptomatic Alzheimer’s disease. Neither trial found slower clinical decline on its main measure at 104 weeks. Semaglutide’s approved uses depend on the product.

FDA-approved antibody · Adult migraine prevention

Emgality 120 mg/mL prefilled pen

Galcanezumab is an antibody that binds CGRP, a signaling peptide involved in migraine. The U.S. label lists a single-pen carton for this under-the-skin injection. The migraine prevention schedule is monthly after a larger first dose.

FDA-approved small molecule · Adult migraine prevention

Qulipta 60 mg tablets, 30-count bottle

Atogepant is a small-molecule drug that blocks the CGRP receptor. It is a daily tablet for prevention. The label lists 60 mg as one strength for episodic migraine and the usual strength for chronic migraine, with exceptions based on other medicines or kidney function.

FDA-approved small molecule · Adult migraine attack treatment

Ubrelvy 100 mg tablets, 10-count carton

Ubrogepant is a small-molecule CGRP receptor blocker approved to treat a migraine attack with or without aura. Its role is relief during an attack.